What's behind Eli Lilly's latest 2.3% stock pullback?

Traders Union
All News
Stocks
Eli lilly slides 2.26% today

Highlights

Eli Lilly reported higher second-quarter revenue and raised full-year guidance as demand for Mounjaro and Zepbound increased.
The company launched new manufacturing sites, expanded access programs, and completed major share repurchases and dividend distributions.
Shares of Eli Lilly trade above key moving averages with a sideways to bullish technical outlook, and a five-day range of $1,148 to $1,209.

Revenue growth and product launches counter persistent selling pressure

Eli Lilly reported a significant increase in second-quarter revenue, driven by strong demand for Mounjaro and Zepbound, and raised its full-year earnings guidance. The company opened new manufacturing sites in Lebanon, Indiana, and Limerick, Ireland, completed large dividend distributions, and carried out $1.6 billion in share repurchases. Additional developments included the launch of Employer Connect to expand access to Zepbound, ongoing legal action regarding unapproved versions of the GLP-1 therapeutic retatrutide, and the completion or advancement of multiple late-stage clinical trials in metabolic health, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes that Eli Lilly's stock remains under notable downside pressure despite strong Q2 financials. Kharitonov sees the price holding above essential moving averages, but warns the overbought signals from oscillators raise red flags for short-term buyers. He highlights risks in the legal disputes and the negative divergence in price action relative to bullish fundamentals. The current setup implies that any breach below $1,148 could trigger accelerated selling. "Recent gains may not be sustainable given oversaturated sentiment and unresolved risks," Kharitonov says.

Viktoras Karapetjanc, expert at Traders Union, believes Eli Lilly's fundamentals remain strong after beating revenue expectations and raising guidance. He points to robust product demand and active expansion efforts as catalysts for further growth. Karapetjanc sees the bullish structure intact, with technicals aligning to support a continued uptrend. "LLY offers compelling setups for investors focused on innovation-driven momentum and multi-year expansion," he states.

Sholanke Dele, market strategist, sees mixed sentiment gripping Eli Lilly. He notes persistent selling pressure despite headline growth in revenue and pipeline news. Dele warns that the recent gap lower signals underlying market caution. "A failure to hold above $1,148 may expose deeper vulnerabilities in current optimism," Dele comments.

Bullish technical structure faces overbought signals and mixed momentum

LLY trades above its 20-day, 50-day, and 200-day moving averages at $1,181, $1,167, and $1,041, respectively, which suggests a bullish structure across all relevant timeframes. Nearest support stands at $1,181, with the closest resistance at $1,184, while the Ichimoku Kijun at $1,173 offers added support just below the current level. Momentum indicators are mixed: the MACD signals buying interest, the ADX reads as neutral, and the RSI is at 55.89 with a bullish outlook. The CCI supports a short-term bullish view, while the Stochastic RSI warns of strong overbought conditions. Bull/Bear Power is positive at 36.71 with an overbought warning, and the Awesome Oscillator confirms bullish momentum. The price remains mid-range intraday with volatility at 1.18%. Overall, technicals show buyers dominating, but short-term oscillators flash caution.

Earlier, analysts noted that Eli Lilly’s outlook remained broadly bullish on the back of strong earnings and expanding product momentum. The current analysis adds a layer of short-term caution amid ongoing selling pressure, with $1,148 now serving as a critical support level that could define the next directional move.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.